{"filing":{"accession_number":"0001628280-26-041883","cik":"0001787306","ticker":"ARQT","company_name":"Arcutis Biotherapeutics, Inc.","form":"8-K","filing_date":"2026-06-09","report_date":null,"primary_document":"arqt-20260605.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1787306/000162828026041883/arqt-20260605.htm"},"events":[{"id":6050,"run_id":5312,"accession_number":"0001628280-26-041883","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Arcutis held its Annual Meeting of Stockholders on June 5, 2026, with shareholders voting on three proposals: election of three Class III directors, ratification of Ernst \u0026 Young LLP as independent auditor, and advisory approval of named executive officer compensation. All three proposals were approved.","company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","filing_date":"2026-06-09","submitted_at":null,"items":[{"id":5494,"accession_number":"0001628280-26-041883","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from Arcutis's June 5, 2026 Annual Meeting of Stockholders. The filing presents tabulated voting outcomes for three proposals: election of three Class III directors, ratification of Ernst \u0026 Young LLP as independent auditor, and advisory approval of named executive officer compensation. All proposals were approved. This is a quintessential Item 5.07 disclosure and material to investors as it documents stockholder actions on governance and compensation matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T20:07:29.221902+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":6051,"run_id":5312,"accession_number":"0001628280-26-041883","anchor_item_number":"8.01","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"The Board approved revisions to the Amended and Restated Non-Employee Director Compensation Program, which establishes annual cash and equity compensation arrangements for non-employee directors.","company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","filing_date":"2026-06-09","submitted_at":null,"items":[{"id":5495,"accession_number":"0001628280-26-041883","item_number":"8.01","item_title":"Other Events","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses Board approval of revisions to the \"Amended and Restated Non-Employee Director Compensation Program,\" which provides annual cash and equity compensation to non-employee directors. This is a compensatory arrangement amendment affecting director compensation, fitting the exec_compensation category. The disclosure is material as it affects the total mix of information about director compensation practices and retention strategies.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T20:07:29.221902+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5494,"accession_number":"0001628280-26-041883","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from Arcutis's June 5, 2026 Annual Meeting of Stockholders. The filing presents tabulated voting outcomes for three proposals: election of three Class III directors, ratification of Ernst \u0026 Young LLP as independent auditor, and advisory approval of named executive officer compensation. All proposals were approved. This is a quintessential Item 5.07 disclosure and material to investors as it documents stockholder actions on governance and compensation matters.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T20:07:29.221902+00:00","company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","filing_date":"2026-06-09"},{"id":5495,"accession_number":"0001628280-26-041883","item_number":"8.01","item_title":"Other Events","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The filing discloses Board approval of revisions to the \"Amended and Restated Non-Employee Director Compensation Program,\" which provides annual cash and equity compensation to non-employee directors. This is a compensatory arrangement amendment affecting director compensation, fitting the exec_compensation category. The disclosure is material as it affects the total mix of information about director compensation practices and retention strategies.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-09T20:07:29.221902+00:00","company_name":"Arcutis Biotherapeutics, Inc.","ticker":"ARQT","filing_date":"2026-06-09"}]}